Skip to main content
OpenTrials
Completed

NCT Number: NCT07050004

Prevalence of Smoking After Lung Transplantation

Smoking is one of the main risk factors for chronic obstructive pulmonary disease (COPD), the primary indication for lung transplantation (LT) in France. Resumption of smoking after transplantation is associated with an increased risk of graft dysfunction, neoplasia and reduced survival. The prevalence of resumption of smoking after transplantation is based on few data available in the literature and is estimated at between 0 and 15%. The aim of this study is to determine the prevalence of smoking in transplantation. These results will enable healthcare professionalś to carry out information, education, prevention and support actions to help patients stop smoking throughout the transplantation process.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Tobacco Smoking Behavior Lung Transplantation Smoking Tobacco Use

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hopital Marie Lannelongue

Le Plessis-Robinson, 92350, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who has undergone a lung transplant (single, double or heart-lung) and is being followed up in a transplant centre in France;
  • Age ≥ 18 years;
  • French-speaking patient;
  • Patient able to give his non-opposition.

Exclusion criteria

  • Patient under guardianship or curatorship;
  • Patient deprived of liberty ;
  • Patient under court protection;
  • Patients who object to the use of their data for this research.

Treatment and study plan

smoking

Behavioral

Patients who agree to take part in the study will complete a questionnaire covering the pre- and post-transplant aspects of smoking on their lifestyle

Primary outcomes

  1. Assessing the prevalence of active smoking in post-lung transplantation sing a questionnaire

    Time frame: one year post transplantation

    Proportion of transplant patients with active smoking

Sponsors and collaborators

Lead sponsor

Fondation Hôpital Saint-Joseph

Other

Registry information

Acronym: TABATRANSPLANT

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Jul 3, 2025
Registry last updated
Jul 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.